Share This Page
Drug Price Trends for TRINTELLIX
✉ Email this page to a colleague
Average Pharmacy Cost for TRINTELLIX
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRINTELLIX 5 MG TABLET | 64764-0720-30 | 16.43923 | EACH | 2025-01-01 |
| TRINTELLIX 10 MG TABLET | 64764-0730-30 | 16.43282 | EACH | 2025-01-01 |
| TRINTELLIX 20 MG TABLET | 64764-0750-30 | 16.43340 | EACH | 2025-01-01 |
| TRINTELLIX 20 MG TABLET | 64764-0750-30 | 15.65101 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Trintellix
Introduction to Trintellix
Trintellix, also known as vortioxetine, is a multimodal antidepressant developed by Lundbeck and Takeda. It is primarily used for the treatment of Major Depressive Disorder (MDD). Here, we will delve into the market analysis and price projections for this medication.
Market Drivers
The market for Trintellix is driven by several key factors:
Launch of New Pipeline Products
The forecast period is expected to see the launch of eight new pipeline products, which will significantly impact the MDD market. These new products, including Trintellix, have higher therapy costs compared to generic SSRIs, SNRIs, and atypical antipsychotics, the most commonly used MDD treatments[1].
Uptake of Recently Approved Drugs
The continued uptake of recently approved drugs such as Spravato, Auvelity, and Vraylar will also drive growth in the MDD market. This includes the increasing number of 12-month total prevalent cases of MDD, expected to rise at an annual growth rate (AGR) of 0.37% during the forecast period[1].
Sales Performance
Current Sales
Trintellix has been a high-performing drug in the market. In 2019, it was the highest-selling drug in its category, with sales of $793 million. This success is attributed to its effectiveness in treating MDD and the lack of a generic version, which maintains its market exclusivity[1].
Regional Performance
The sales of Trintellix are strong across various regions. In the U.S., sales growth has been driven by price increases and higher demand. In Europe and international markets, countries like Spain, Italy, and Japan have seen significant growth, contributing to an overall revenue increase of 11% in constant exchange rates (CER) and 9% in Danish kroner (DKK) for the first half of 2024[4].
Pricing and Cost
High Cost of Trintellix
Trintellix is known for its high cost. American patients pay approximately $525 for 30 tablets, which translates to about $17.50 per tablet. This results in an annual cost of over $6,000 for patients in the United States[2].
Savings Options
To mitigate the high cost, patients can explore options such as purchasing the medication from online Canadian pharmacies, which can offer savings of up to 37%. For example, 30 tablets of brand-name Trintellix can cost around $310, or about $11 per tablet, when bought from such sources[2].
Cost-Effectiveness Analysis
Pharmacoeconomic Evaluation
A cost-utility analysis conducted from the perspective of a Canadian publicly funded health care payer shows that Trintellix is more expensive but also more effective than many of its comparators. The incremental cost-utility ratio (ICUR) for Trintellix compared to other antidepressants ranges from $10,700 to $89,785 per quality-adjusted life-year (QALY)[5].
Comparative Costs
The analysis indicates that for Trintellix to be considered cost-effective, it would need to be priced similarly to generic versions of other antidepressants, such as duloxetine, bupropion, or escitalopram, which would require a significant price reduction (67% to 90%)[5].
Market Projections
Revenue Growth
Lundbeck's financial reports indicate strong revenue growth for Trintellix. For the first half of 2024, the revenue from Trintellix reached DKK 2,351 million, representing an 11% growth in CER and 9% in DKK. This growth is expected to continue, driven by increased demand and market share gains in key markets[4].
Future Outlook
The sales outlook for 2024 has been updated to reflect higher expectations for Trintellix, along with other strategic brands like Rexulti and Vyepti. The strong performance of these drugs is expected to contribute significantly to Lundbeck's total revenue, with the U.S., Canada, Spain, Italy, and France being the largest markets[4].
Challenges and Opportunities
Generic Competition
One of the significant challenges for Trintellix is the potential introduction of generic versions. Currently, there is no generic version available, but once generics enter the market, they could significantly reduce the pricing power and market share of Trintellix[2].
Expanding Market Reach
Despite the high cost, Trintellix has opportunities for growth in expanding its market reach. Increasing awareness and diagnosis of MDD, along with the drug's effectiveness, can drive demand. Additionally, strategic pricing and savings options can help make the medication more accessible to a broader patient base[1][2].
Key Takeaways
- High Sales Performance: Trintellix has been a top-selling drug in the MDD market, with significant sales in 2019 and continued growth in subsequent years.
- Regional Strength: The drug performs well in various regions, including the U.S., Europe, and international markets.
- High Cost: Trintellix is expensive, with annual costs exceeding $6,000 for American patients, but savings options are available.
- Cost-Effectiveness: While more expensive, Trintellix is more effective than many comparators, as shown in cost-utility analyses.
- Future Growth: Strong revenue growth is projected, driven by increased demand and market share gains.
FAQs
1. What is Trintellix used for? Trintellix, or vortioxetine, is used for the treatment of Major Depressive Disorder (MDD).
2. Why is Trintellix so expensive? Trintellix is expensive due to its brand-name status and the lack of a generic version. American patients pay around $525 for 30 tablets, resulting in an annual cost of over $6,000.
3. How can patients save money on Trintellix? Patients can save money by purchasing Trintellix from online Canadian pharmacies, which can offer savings of up to 37%.
4. What is the cost-effectiveness of Trintellix compared to other antidepressants? Trintellix is more expensive but also more effective than many comparators. The ICUR ranges from $10,700 to $89,785 per QALY, indicating it needs significant price reductions to be considered cost-effective against generics[5].
5. What are the market projections for Trintellix? The market projections indicate strong revenue growth for Trintellix, driven by increased demand and market share gains in key markets. The sales outlook for 2024 has been updated to reflect higher expectations for Trintellix and other strategic brands[4].
Sources
- GlobalData: Major Depressive Disorder Market 2024 - GlobalData
- Northwest Pharmacy: Why is Trintellix So Expensive? (& How to Get Up to 37% Off)
- National Institute of Public Health: Cost-effectiveness evaluation of Vortioxetine Hydrobromide (Trintellix)
- Lundbeck: Q2 2024_Final.pdf - Lundbeck
- CADTH: CDR Pharmacoeconomic Review Report for Trintellix
More… ↓
